BRNS Company Profile and Key Details

NASDAQ : BRNS

Barinthus Biotherapeutics

$0.66

0.02+3.15%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Barinthus Biotherapeutics plc (BRNS) stock surged +3.15%, trading at $0.66 on NASDAQ, up from the previous close of $0.64. The stock opened at $0.64, fluctuating between $0.63 and $0.68 in the recent session.

Stock Snapshot

0.635

Prev. Close

26.76M

Market Cap

0.63

Day Low

-0.4

P/E Ratio

-1.64

EPS (TTM)

N/A

Cash Flow per Share

0.64

Open

40.85M

Number of Shares

0.675

Day High

88.42%

Free Float in %

N/A

Book Value

17.36K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 05, 2026	0.64	0.67	0.63	0.66	17.57K
May 04, 2026	0.63	0.64	0.63	0.64	8.45K
Apr 30, 2026	0.61	0.66	0.61	0.65	28.48K
Apr 29, 2026	0.60	0.63	0.59	0.60	11.29K
Apr 28, 2026	0.65	0.65	0.61	0.61	10.8K
Apr 27, 2026	0.63	0.64	0.59	0.63	13.5K
Apr 23, 2026	0.66	0.68	0.59	0.64	24.95K
Apr 22, 2026	0.61	0.68	0.60	0.63	31.46K
Apr 21, 2026	0.59	0.62	0.59	0.59	20.14K
Apr 20, 2026	0.62	0.62	0.59	0.59	36.43K
Apr 17, 2026	0.59	0.62	0.59	0.59	15K
Apr 16, 2026	0.61	0.61	0.59	0.59	16.21K
Apr 14, 2026	0.60	0.62	0.55	0.60	35.04K
Apr 13, 2026	0.58	0.61	0.55	0.55	27.71K
Apr 10, 2026	0.60	0.60	0.55	0.57	19.75K
Apr 09, 2026	0.56	0.56	0.55	0.55	9.83K
Apr 08, 2026	0.55	0.61	0.54	0.59	21.61K
Apr 07, 2026	0.57	0.62	0.54	0.54	20.89K
Apr 06, 2026	0.58	0.62	0.54	0.57	8.44K
Apr 02, 2026	0.57	0.62	0.54	0.60	19.13K

Contact Details

Didcot, OX11 0DF

United Kingdom

https://www.barinthusbio.com 441 865 818808

About Company

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Stock Peers

ARGX

-16.39-2.02%

argenx SE$794.70 REGN

-6.94-0.98%

Regeneron Pharmaceuticals, Inc.$702.27 UTHR

-9.02-1.55%

United Therapeutics Corporation$572.20 MDGL

-16.19-3.12%

Madrigal Pharmaceuticals, Inc.$502.47 VRTX

-5.49-1.28%

Vertex Pharmaceuticals Incorporated$424.36 PRAX

-4.31-1.28%

Praxis Precision Medicines, Inc.$333.30 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

3.185+1.07%

Alnylam Pharmaceuticals, Inc.$301.11 KRYS

-2.38-0.83%

Krystal Biotech, Inc.$284.57 LGND

3.94+1.73%

Ligand Pharmaceuticals Incorporated$232.30

Company Overview

Barinthus Biotherapeutics plc (NASDAQ:BRNS) closed at $0.66 USD, gaining $0.02 (3.15%) from the previous close of $0.64. The stock is currently mid-range between its 52-week high and low $0.51 and $2.92. With a market capitalization of about $26.76 million, Barinthus Biotherapeutics plc is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.60). Key stats such as the average daily volume over the past year has been around 40.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Didcot, None, Barinthus Biotherapeutics plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO William James Enright, the company employs approximately 105 people and listed since April 30, 2021. Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -12.03%, SMA50 -16.81%, SMA200 -42.17%). The stock’s 14-day RSI is 38.15 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.03% below its high and over 4.11% above its low. Average 10-day trading volume of 15.01 thousand shares is below the 3-month average of 42.85 thousand, indicating normal recent market interest.

Valuation Metrics

Barinthus Biotherapeutics plc trades at a P/E ratio of -0.53, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.42 suggesting the stock is closer to book value. The P/FCF stands at -0.76, also above market averages.

Dividend & Fair Value

Barinthus Biotherapeutics plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.46. This means the shares are trading below this model’s fair value.

Frequently Asked Questions

What is the current Barinthus Biotherapeutics plc (BRNS) stock price?

Barinthus Biotherapeutics plc (NASDAQ: BRNS) stock price is $0.66 in the last trading session. During the trading session, BRNS stock reached the peak price of $0.68 while $0.63 was the lowest point it dropped to. The percentage change in BRNS stock occurred in the recent session was 3.15% while the dollar amount for the price change in BRNS stock was $0.02.

BRNS's industry and sector of operation?

The NASDAQ listed BRNS is part of Biotechnology industry that operates in the broader Healthcare sector. Barinthus Biotherapeutics plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BRNS?

No Data

How BRNS did perform over past 52-week?

BRNS's closing price is 27.93% higher than its 52-week low of $0.51 where as its distance from 52-week high of $2.92 is -77.57%.

How many employees does BRNS have?

Number of BRNS employees currently stands at 105.

Link for BRNS official website?

Official Website of BRNS is: https://www.barinthusbio.com

How do I contact BRNS?

BRNS could be contacted at phone 441 865 818808 and can also be accessed through its website. BRNS operates from Zeus Building, Didcot, OX11 0DF, United Kingdom.

How many shares of BRNS are traded daily?

BRNS stock volume for the day was 17.36K shares. The average number of BRNS shares traded daily for last 3 months was 40.74K.

What is the market cap of BRNS currently?

The market value of BRNS currently stands at $26.76M with its latest stock price at $0.66 and 40.85M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

0.635

Prev. Close

26.76M

Market Cap

0.63

Day Low

-0.4

P/E Ratio

-1.64

EPS (TTM)

N/A

Cash Flow per Share

0.64

Open

40.85M

Number of Shares

0.675

Day High

88.42%

Free Float in %

N/A

Book Value

17.36K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 05, 2026	0.64	0.67	0.63	0.66	17.57K
May 04, 2026	0.63	0.64	0.63	0.64	8.45K
Apr 30, 2026	0.61	0.66	0.61	0.65	28.48K
Apr 29, 2026	0.60	0.63	0.59	0.60	11.29K
Apr 28, 2026	0.65	0.65	0.61	0.61	10.8K
Apr 27, 2026	0.63	0.64	0.59	0.63	13.5K
Apr 23, 2026	0.66	0.68	0.59	0.64	24.95K
Apr 22, 2026	0.61	0.68	0.60	0.63	31.46K
Apr 21, 2026	0.59	0.62	0.59	0.59	20.14K
Apr 20, 2026	0.62	0.62	0.59	0.59	36.43K
Apr 17, 2026	0.59	0.62	0.59	0.59	15K
Apr 16, 2026	0.61	0.61	0.59	0.59	16.21K
Apr 14, 2026	0.60	0.62	0.55	0.60	35.04K
Apr 13, 2026	0.58	0.61	0.55	0.55	27.71K
Apr 10, 2026	0.60	0.60	0.55	0.57	19.75K
Apr 09, 2026	0.56	0.56	0.55	0.55	9.83K
Apr 08, 2026	0.55	0.61	0.54	0.59	21.61K
Apr 07, 2026	0.57	0.62	0.54	0.54	20.89K
Apr 06, 2026	0.58	0.62	0.54	0.57	8.44K
Apr 02, 2026	0.57	0.62	0.54	0.60	19.13K

Contact Details

Didcot, OX11 0DF

United Kingdom

https://www.barinthusbio.com 441 865 818808

About Company

Stock Peers

ARGX

-16.39-2.02%

argenx SE$794.70 REGN

-6.94-0.98%

Regeneron Pharmaceuticals, Inc.$702.27 UTHR

-9.02-1.55%

United Therapeutics Corporation$572.20 MDGL

-16.19-3.12%

Madrigal Pharmaceuticals, Inc.$502.47 VRTX

-5.49-1.28%

Vertex Pharmaceuticals Incorporated$424.36 PRAX

-4.31-1.28%

Praxis Precision Medicines, Inc.$333.30 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

3.185+1.07%

Alnylam Pharmaceuticals, Inc.$301.11 KRYS

-2.38-0.83%

Krystal Biotech, Inc.$284.57 LGND

3.94+1.73%

Ligand Pharmaceuticals Incorporated$232.30

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 9.47% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 506.06% upside. The low target suggests 506.06% downside. The mean target is $4.00. This offers 506.06% upside. Barinthus Biotherapeutics plc earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -50.0%. The prior quarter beat by -32.5%. Over the last six quarters, Apple has recorded several small beats. These include 2.0% in March 20, 2025.

Shareholding & Insider Activity

Barinthus Biotherapeutics plc has 40.72 million shares outstanding. The public float is 35.68 million shares, elevated short interest at 0.05% of float. This equals 13.43 thousand shares. The short ratio is 0.32 days. Institutional investors hold 51.53% of the float. Insiders own 13.65%.

Financial & Profitability Overview

Over the trailing twelve months, Barinthus Biotherapeutics has not generated any revenue.
On valuation metrics, Barinthus Biotherapeutics trades at a P/E of -0.53, P/S of 0.00 and P/B of 0.42. The current ratio is 6.05 and quick ratio is 6.05. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -205.67 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of -3.31.

Price Forecast & Outlook

Our AI price prediction model suggests that Barinthus Biotherapeutics plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.29%, with price expected at $0.67 by May 19, 2026, within a range of $0.64 to $0.71 3-Month Outlook: Projected rise of 43.51%, reaching $0.94 by August 03, 2026, with a range of $0.90 to $0.99. 1-Year Outlook: Projected loss of -28.24%, with price at $0.47 by May 05, 2027, within a range of $0.00 to $0.07.

Key Takeaways

Barinthus Biotherapeutics plc (NASDAQ:BRNS) shares are flat 2.84% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Barinthus Biotherapeutics plc trading at a premium to the broader market with a P/E of -0.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.93, suggesting 652.67% upside. Our AI forecast model points to short-term strength (2.29% over two weeks), a medium-term rise (43.51% over three months), and a longer-term loss (-28.24% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Barinthus Biotherapeutics plc (BRNS) stock price?

BRNS's industry and sector of operation?

Who are the executives of BRNS?

No Data

How BRNS did perform over past 52-week?

BRNS's closing price is 27.93% higher than its 52-week low of $0.51 where as its distance from 52-week high of $2.92 is -77.57%.

How many employees does BRNS have?

Number of BRNS employees currently stands at 105.

Link for BRNS official website?

Official Website of BRNS is: https://www.barinthusbio.com

How do I contact BRNS?

BRNS could be contacted at phone 441 865 818808 and can also be accessed through its website. BRNS operates from Zeus Building, Didcot, OX11 0DF, United Kingdom.

How many shares of BRNS are traded daily?

BRNS stock volume for the day was 17.36K shares. The average number of BRNS shares traded daily for last 3 months was 40.74K.

What is the market cap of BRNS currently?

The market value of BRNS currently stands at $26.76M with its latest stock price at $0.66 and 40.85M of its shares outstanding.

Employees	105
Beta	-0.62
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

Employees	105
Beta	-0.62
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

BRNS Company Profile and Key Details

Barinthus Biotherapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview